The first patient, born in 2002, was referred for muscle biopsy and genetic sampling due to high levels of Creatine Kinase in 2003. Initial genetic analyses at age of 12 months revealed large exon deletion behind exon 44. Until this time patient reached many gross motor skill milestones, such as holding his head up, rolling over, sitting, and standing, at normal times. Motoric abnormalities were observed at the age of 2 years, involving suspected lordotic posture while standing. Gowers sign was noted at the age of 4 years. Proximal musculature of arms, pelvis and legs was progressively weakening. Additional genetic analyses were performed at age of 6, using Multiplex Ligation-dependent Probe Amplification (MLPA) and deletion of exon 45-50 (DelEX 45-50) was observed. As confirmation also mRNA test of dystrophin gene was performed in patient and mother, resulting in occurring deletion in nucleotide position 6439-7309 -corresponding to 45-50 exons, causing shortened mRNA and truncated protein. At the age of 6 years a rapid decrease in 6 minute walking test was recorded and by the age of 9, the patient was confined to wheelchair / motorized chair and remained dependent on this support. Dyspnea and ankle swelling was observed recently (age 12). Cardiac magnetic resonance was performed, yet without significant decrease in ejection fraction. Also the echocardiographic parameters were normal.
The second patient born in 1998 was examined because of suspicion for delayed motoric development, suspected Gowers sign and progressing lordosis. Conducted was DNA analysis which found deletion of exons 45-49 and 50 in dystrophin gene.
MLPA analysis was conducted in 2010 and confirmed previous findings. Since the age of 7 the patient is bound to wheelchair. Dyspnea was observed infrequently and recently ventilator support during the sleep period had to be applied (age 16).
Cell line description and identification
The DMD patient specific hiPSC lines are karyotypicaly healthy (both 46, XY, Supplementary Fig1 ) and short tandem repeats analysis (unpublished data) confirmed their origin from the patient derived fibroblasts. MLPA analysis showed presence of the same mutation in the DMD hiPSC lines as was previously detected in the patients (patient 1: deleted exons 45-50, referred to as DMD02; and patient 2: deleted exons 48-50, referred to as DMD03; see The CRISPR mutated cDMD hESC line was derived from CCTL14 WT ESC line, 46, XX, der(18) , with a derived chromosome 18. After CRISPR/Cas9 DMD targeted mutation introduction, the derived chromosome 18 remained present in the cDMD hESC (46X, del(X), der(8), t(8;12). The CRISPR/Cas9 targeting resulted in a complete deletion of p arm of one of the X chromosomes as visible in the karyotypes (Fig. S1 ) which resulted in a complete loss of one allele of DMD gene. This mutation lead to a complete loss of dystrophin mRNA and protein expression (Figure 1 ). The karyotype analysis also revealed a reciprocal translocation of chromosomes 8 and 12 (confirmed by FISH, Fig. S1 ). No other changes were detected via karyotyping.
Whole genome sequencing based copy number variation comparisons between cDMD and CCTL14 hESC lines confirmed deletion on one copy of chromosome X p arm. An alignment to genome (hg19) showed additional mutation on chromosome 18, present in both the source CCTL14 and cDMD. No other changes were detected with used resolution, as the reciprocal translocation found by FISH analysis is compensated. XY) similarly to the original fibroblasts. cDMD line was derived from CCTL14 line that had karyotype 46, XX, der(18). Next to this change, the cDMD showed karyotype 46, X, del(X), der(18), t(8;12) with reciprocal translocation confirmed by FISH. The reciprocal translocation of chromosomes 8 and 12 was probably due to off target cleavage of the CRISPR gRNA used for the mutation introduction. 
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: Expression downregulation efficiency of iNOS, nNOS and eNOS using siRNA.
All silencing experiments were performed with immunocytological control of expression decrease using corresponding NOS isoforms' specific antibodies.
Untreated sample was used for comparison (control). Images were acquired with same parameters of acquisition. Line represents 50 µ m, NOS isoforms are in red, nuclei are counterstained with DAPI (blue). 
